

NIH to Conduct Clinical Trial Using Kiadis Pharma's Theralux™ ATIR Technology in Allogeneic Stem Cell Transplantation

Supporting Data Presented at Annual American Society of Hematology Meeting

Orlando, December 13, 2006 – During the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH), Dr. Stephan Mielke of the Hematology Branch at the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), presented results on Theralux™-ATIR, a technology under development by Kiadis Pharma B.V. (formerly Celmed BioSciences Inc.). The data demonstrated that host-reactive T cells can be selectively eliminated from donor stem cell allografts under clinical scale conditions. The manipulated T cell allograft left behind a broad repertoire of T cells which can provide immunity against infection and prevent disease relapse.

In an oral presentation titled "High Efficiency Clinical Scale Selective Depletion of Alloreacting T Cells Using Expanded T Lymphocytes as Antigen-Presenting Cells and a TH9402-Based Photodepletion Technique in HLA-Mismatched and Matched Donor-Recipient Pairs," Dr. Mielke reported on nine successfully performed clinical scale procedures evaluating Theralux™-ATIR as a feasible alternative to current selective T cell depletion strategies. In mismatched pairs a reduction of alloreactivity of 2.5 logs was achieved and in matched pairs the precursor frequency of host-reactive T cells could be reduced below the threshold of 1:100,000 in all studied pairs.

The objective of Theralux™-ATIR in this setting is to reduce the incidence of complications normally associated with indiscriminate depletion of the entire T cell constitution, while preserving the graft versus leukemia (GvL) effect thought to be essential for a benefit in the control of the malignant disease.

Dr. Mielke's results suggest that Theralux™-ATIR is efficient for the selective depletion of alloreactive T cells from matched and mismatched blood stem cell allografts while retaining important third-party responses. According to Dr. John Barrett, Chief of the Allogeneic Stem Cell Transplantation Section of the Hematology Branch at the NHLBI, the next step will be to conduct a clinical trial to treat patients with hematological malignancies.

"The promise of Theralux™-ATIR was critical in the merger of Celmed BioSciences of Montreal and Kiadis," said Manja Bouman, CEO, Kiadis Pharma. "We are very pleased that the NIH is using Kiadis Pharma's Theralux™-ATIR technology in their clinical trial."

Below is a list of all abstracts using *Kiadis Pharma's Theralux™-ATIR technology* presented at the 2006 ASH Meeting:

Stephan Mielke *et al.* "High Efficiency Clinical Scale Selective Depletion of Alloreacting T Cells Using Expanded T Lymphocytes as Antigen-Presenting Cells and a TH9402-Based Photodepletion Technique in HLA-Mismatched and Matched Donor-Recipient Pairs"

Denis Claude Roy *et al.* "Phase I Clinical Study of Donor Lymphocyte Infusion Depleted of Alloreactive T Cells After Haplotype Mismatched Myeloablative Stem Cell Transplantation to Limit Infections and Malignant Relapse Without Causing Graft-Versus-Host Disease"

NgocDiep Le *et al.* "Prevention of Graft Versus Host Disease by Selective Depletion of Alloreactive T Cells"

About Kiadis Pharma B.V.

Kiadis Pharma is fully dedicated to in-house pharmaceutical product development with extensive experience in oncology and full ownership of its products under development. The company has developed a number of small molecule drugs in various stages of clinical development from its proprietary technology platforms Theralux™, BioSelact™ and ECTA. Kiadis Pharma is headquartered in the Netherlands with facilities in Groningen, the Netherlands and Montreal, Canada.

About NIH

Founded in 1887, the National Institutes of Health today is one of the world's foremost medical research centers, and the Federal focal point for medical research in the United States. The NIH, comprising 27 separate Institutes and Centers, is one of eight health agencies of the Public Health Service which, in turn, is part of the U.S. Department of Health and Human Services.

The NIH mission is to uncover new knowledge that will lead to better health for everyone. NIH works toward that mission by: conducting research in its own laboratories; supporting the research of non-Federal scientists in universities, medical schools, hospitals, and research institutions throughout the country and abroad; helping in the training of research investigators; and fostering communication of medical and health sciences information.

For more information, please contact:

[Kiadis Pharma B.V.](#)

Manja Bouman, CEO

Email: m.bouman@kiadis.com

Telephone: +31 (0)50 547 4270